|
gptkbp:instanceOf
|
gptkb:cancer
|
|
gptkbp:accountsFor
|
about 15% of lung cancers
|
|
gptkbp:alsoKnownAs
|
gptkb:SCLC
|
|
gptkbp:cause
|
gptkb:Lambert-Eaton_myasthenic_syndrome
gptkb:paraneoplastic_syndromes
gptkb:Cushing_syndrome
gptkb:SIADH
|
|
gptkbp:characterizedBy
|
rapid growth
early metastasis
|
|
gptkbp:commonIn
|
older adults
smokers
|
|
gptkbp:detects
|
gptkb:chest_X-ray
gptkb:CT_scan
MRI
PET scan
|
|
gptkbp:diagnosedBy
|
imaging
biopsy
|
|
gptkbp:expressedIn
|
neuroendocrine markers
|
|
gptkbp:firstDescribed
|
1926
|
|
gptkbp:hasHigh
|
necrosis
mitotic rate
|
|
gptkbp:hasPoorerPrognosisThan
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:ICD-10_code
|
C34
|
|
gptkbp:MeSH_ID
|
D002289
|
|
gptkbp:mostCommonRiskFactor
|
tobacco smoking
|
|
gptkbp:originatedIn
|
lung epithelial cells
|
|
gptkbp:prognosis
|
poor
|
|
gptkbp:rareIn
|
non-smokers
|
|
gptkbp:stagedBy
|
extensive stage
limited stage
|
|
gptkbp:subspecies
|
combined small cell carcinoma
small cell carcinoma
|
|
gptkbp:symptom
|
weight loss
cough
chest pain
dyspnea
|
|
gptkbp:treatment
|
gptkb:durvalumab
gptkb:radiation_therapy
gptkb:immunotherapy
gptkb:antineoplastic_agent
gptkb:atezolizumab
gptkb:carboplatin
gptkb:irinotecan
gptkb:topotecan
gptkb:cisplatin
chemotherapy
surgery (rarely)
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
Small cell lung cancer
|